Warning for patients with asthma regarding inhalers
GlaxoSmithKline, the manufacturer of the popular steroid inhaler Flovent used to treat asthma symptoms, is set to phase out the medication as it prepares to introduce a generic version. The company announced that starting on Jan. 1, 2024, it would cease the production of Flovent HFA and Flovent Diskus, replacing them with an identical generic version. While GSK believes this will provide potentially lower cost options for patients, some healthcare professionals have expressed concerns, fearing negative impacts on both patients’ finances and health.
About Flovent
Flovent is an inhaler containing the prescription corticosteroid fluticasone and is used to treat asthma long-term in patients ages 4 and older. It has been on the market since 2000.
Reasons behind the Generic Replacement
The decision to switch to a generic version of Flovent is connected to new rules about drug pricing. Under the new law, GSK would have been obligated to pay rebates related to the drug’s price increases starting next year. Flovent’s price increased 41% between 2013 and 2018, and has experienced a 47% increase since 2014.
Medical Professionals’ Concerns
Pediatricians are particularly worried about future changes in the drug’s delivery mechanism, especially if some insurers only cover breath-actuated inhalers. They argue that such inhalers aren’t suitable for treating children with certain asthma conditions.
Available Alternatives
While alternatives to Flovent are available, physicians advise families to refill their prescriptions before the end of the year to allow time to determine the best options for their situation. Physicians also recommend that parents and patients discuss potential alternatives with their doctors and inquire with their insurers about coverage for those alternatives well in advance.
